Document:

EX-10.2

 Exhibit 10.2 

INTELLECTUAL PROPERTY SECURITY AGREEMENT 

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (“Agreement”) dated as of May 14, 2015, is made by Nanosphere,
Inc., a Delaware corporation (“Grantor”), in favor of NSPH Funding LLC (“Collateral Agent”) in its capacity as collateral agent for the Lenders (as defined below). 

RECITALS 
 A. Grantor has
entered into a Loan and Security Agreement with certain financial institutions party thereto (the “Lenders”) and Collateral Agent, in its capacity as collateral agent for itself and the Lenders, dated as of the date hereof (as
amended, restated, or otherwise modified from time to time, the “Loan Agreement”). All capitalized terms used but not defined herein shall have the respective meanings given to them in the Loan Agreement. 

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent for its benefit and the benefit of the Lenders a
security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (as defined in the Loan Agreement). 

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral
security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows: 

AGREEMENT 
 1. Grant of
Security Interest. To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent for its benefit and the benefit of the Lenders a security interest in all of Grantor’s right, title and interest in, to
and under its intellectual property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following: 

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and
derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached
hereto (collectively, the “Copyrights”); 
 (b) Any and all trade secrets, and any and all intellectual property rights in
computer software and computer software products now or hereafter existing, created, acquired or held; 
 (c) Any and all design rights that
may be available to Grantor now or hereafter existing, created, acquired or held; 
 (d) All patents, patent applications and like
protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and
patent applications set forth on Exhibit B attached hereto (collectively, the “Patents”); 
 (e) Any trademark and
servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without
limitation those set forth on Exhibit C attached hereto (collectively, the “Trademarks”); 
 (f) All mask works or
similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “Mask Works”); 

 (g) Any and all claims for damages by way of past, present and future infringements of any of the
rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above; 

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising
from such use to the extent permitted by such license or rights; 
 (i) All amendments, extensions, renewals and extensions of any of the
Copyrights, Trademarks, Patents, or Mask Works; and 
 (j) All proceeds and products of the foregoing, including without limitation all
payments under insurance or any indemnity or warranty payable in respect of any of the foregoing. 
 Notwithstanding the foregoing,
“Intellectual Property Collateral” shall not include (i) any United States intent-to-use trademark applications to the extent that and solely during the period in which the grant of a security interest therein would impair,
under applicable federal law, the registrability of such applications or the validity or enforceability of registrations issuing from such applications; or (ii) any licenses or other rights to use any of the Copyrights, Patents, Trademarks, or
Mask Works to the extent (x) that the terms of such license or other rights validly prohibits the creation by Grantor of a security interest therein or thereon or (y) to the extent that applicable law prohibits the creation of a security
interest therein or thereon but only to the extent and for so long as such license, terms of any other right to use, or applicable law validly prohibits the creation of a Lien on such property in favor of the Collateral Agent. 

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any
other government officials to record and register this Agreement upon request by Collateral Agent. 
 Grantor hereby authorizes Collateral
Agent to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement and (b) file a duplicate original of
this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral. 
 3. Loan Documents. This Agreement
has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The
rights and remedies of Collateral Agent with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies. 

4. Execution in Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number
of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 

5. Successors and Assigns. The provisions of this Agreement shall inure to the benefit the parties hereto and their respective
successors and assigns. Grantor shall not assign its obligations under this Agreement without Collateral Agent’s express prior written consent, and any such attempted assignment shall be void and of no effect. Collateral Agent may assign,
transfer, or endorse its rights hereunder pursuant to the terms of the Loan Agreement without prior notice to Grantor, and all of such rights shall inure to the benefit of Collateral Agent’s successors and assigns. 

6. Governing Law. This Agreement has been negotiated and delivered to Collateral Agent in the State of New York, and shall have been
accepted by Collateral Agent in the State of New York. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of
laws of any other jurisdiction. 
 [Signature page follows.] 

 IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be
duly executed by its officers thereunto duly authorized as of the first date written above. 
  

	
	 GRANTOR:

	
	 NANOSPHERE, INC., a Delaware corporation

	
	 /s/ Michael McGarrity

	 By: Michael McGarrity

	 Title: CEO

	
	 COLLATERAL AGENT:

	
	NSPH FUNDING LLC, a Delaware limited liability company
	
	 /s/ Stephen J. DeNelsky

	 By: Stephen J. DeNelsky

	 Title: President

 [Signature Page to IP Security Agreement] 

 EXHIBIT A 

Copyrights 

 U.S. COPYRIGHT OFFICE SCHEDULE 

SOFTWARE NOT REGISTERED WITH THE U.S. COPYRIGHT OFFICE 

Verigene® Operating System 

SOFTWARE REGISTERED WITH THE U.S. COPYRIGHT OFFICE 

None. 
 April 1, 2015 

 EXHIBIT B 

Patents 

 NANOSPHERE COLLATERAL — PATENT SCHEDULE 

(patent numbers are hyperlinked; place cursor over number) 
  

													
	 	  	 	  	 TITLE
	  	FILING
DATE	  	PATENT
NO.	  	ISSUE
DATE	  	OWNERSHIP
RIGHTS
							
		  		  	UNITED STATES PATENTS	  		  		  		  	
							
	 1
	  	00-713-B1	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	8/7/2001	  	6,773,884	  	8/10/2004	  	Joint with
Northwestern
University
							
	 2
	  	00-713-C	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	6/25/1999	  	6,361,944	  	3/26/2002	  	Joint with
Northwestern
University
							
	 3
	  	00-713-I	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	6/26/2000	  	6,506,564	  	1/14/2003	  	Joint with
Northwestern
University
							
	 4
	  	00-713-I-01	  	Nanoparticles having oligonucleotides attached thereto and uses thereof	  	9/20/2001	  	6,582,921	  	6/24/2003	  	Joint with
Northwestern
University
							
	 5
	  	00-713-I-02	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	9/20/2001	  	6,759,199	  	7/6/2004	  	Joint with
Northwestern
University
							
	 6
	  	00-713-I-03	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	9/20/2001	  	6,645,721	  	11/11/2003	  	Joint with
Northwestern
University
							
	 7
	  	00-713-I-04	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	9/28/2001	  	6,610,491	  	5/25/2004	  	Joint with
Northwestern
University
							
	 8
	  	00-713-I-05	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	9/28/2001	  	6,673,548	  	1/6/2004	  	Joint with
Northwestern
University
							
	 9
	  	00-713-I-06	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	9/28/2001	  	6,740,491	  	5/25/2004	  	Joint with
Northwestern
University
							
	 10
	  	00-713-I-07	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/10/2001	  	6,709,825	  	3/23/2004	  	Northwestern
University
							
	 11
	  	00-713-I-08	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/10/2001	  	7,259,252	  	8/21/2007	  	Joint with
Northwestern
University
							
	 12
	  	00-713-I-09	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/10/2001	  	6,878,814	  	4/12/2005	  	NSPH
							
	 13
	  	00-713-I-10	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/10/2001	  	6,720,411	  	4/13/2004	  	NSPH

  

					
	 Page 1/13
	  	 	May 13, 2015	  

													
	 	  	 	  	 TITLE
	  	FILING
DATE	  	PATENT
NO.	  	ISSUE
DATE	  	OWNERSHIP
RIGHTS
							
	 14
	  	00-713-I-11	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/11/2001	  	6,677,122	  	1/13/2004	  	NSPH
							
	 15
	  	00-713-I-13	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/11/2001	  	7,098,320	  	8/29/2006	  	Northwestern
University
							
	 16
	  	00-713-I-14	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/11/2001	  	6,861,221	  	3/1/2005	  	NSPH
							
	 17
	  	00-713-I-15	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/11/2001	  	6,828,432	  	12/7/2004	  	Joint with
Northwestern
University
							
	 18
	  	00-713-I-16	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/12/2001	  	6,903,207	  	6/7/2005	  	Joint with
Northwestern
University
							
	 19
	  	00-713-I-17	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/12/2001	  	6,818,753	  	11/16/2004	  	NSPH
							
	 20
	  	00-713-I-18	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/12/2001	  	6,682,895	  	1/27/2004	  	NSPH
							
	 21
	  	00-713-I-19	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/12/2001	  	6,986,989	  	1/17/2006	  	NSPH
							
	 22
	  	00-713-I-20	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/12/2001	  	6,720,147	  	4/13/2004	  	Joint with
Northwestern
University
							
	 23
	  	00-713-I-21	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/12/2001	  	6,812,334	  	11/2/2004	  	Joint with
Northwestern
University
							
	 24
	  	00-713-I-22	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/15/2001	  	6,777,186	  	8/17/2004	  	Joint with
Northwestern
University
							
	 25
	  	00-713-I-23	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/12/2001	  	6,902,895	  	6/7/2005	  	Northwestern
University
							
	 26
	  	00-713-I-24	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/12/2001	  	6,730,269	  	5/4/2004	  	NSPH
							
	 27
	  	00-713-I-25	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/12/2001	  	6,969,761	  	11/29/2005	  	NSPH
							
	 28
	  	00-713-I-26	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	4/9/2003	  	6,962,786	  	11/8/2005	  	Joint with
Northwestern
University
							
	 29
	  	00-713-I-27	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	2/2/2007	  	8,323,888	  	12/4/2012	  	Joint with
Northwestern
University

  

					
	 Page 2/13
	  	 	May 13, 2015	  

													
	 	  	 	  	 TITLE
	  	FILING
DATE	  	PATENT
NO.	  	ISSUE
DATE	  	OWNERSHIP
RIGHTS
							
	 30
	  	00-713-L	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/20/2000	  	6,495,324	  	12/17/2002	  	Joint with
Northwestern
University
							
	 31
	  	00-713-M	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/20/2000	  	6,417,340	  	7/9/2002	  	Joint with
Northwestern
University
							
	 32
	  	00-714-G	  	Nanoparticles with polymer shells	  	11/30/1999	  	7,115,688	  	10/3/2006	  	NSPH
							
	 33
	  	00-715-A	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	1/12/2001	  	6,767,702	  	7/27/2004	  	Joint with
Northwestern
University
							
	 34
	  	00-715-B	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	11/18/2003	  	7,250,499	  	7/31/2007	  	Joint with
Northwestern
University
							
	 35
	  	00-1085-A	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	3/28/2001	  	6,750,016	  	6/15/2004	  	Joint with
Northwestern
University
							
	 36
	  	00-1085-G	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	8/13/2003	  	7,208,587	  	4/24/2007	  	Joint with
Northwestern
University
							
	 37
	  	00-1086-A	  	Method of detection by enhancement of silver staining	  	7/11/2001	  	6,602,669	  	8/5/2003	  	Northwestern
University
							
	 38
	  	00-1124-A	  	Silver stain removal by chemical etching and sonication	  	11/30/2001	  	6,726,847	  	4/27/2004	  	Northwestern
University
							
	 39
	  	00-1272-C	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	12/7/2001	  	6,984,491	  	1/10/2006	  	Joint with
Northwestern
University
							
	 40
	  	01-599-A	  	Bioconjugate-nanoparticle probes	  	11/8/2002	  	7,186,814	  	3/6/2007	  	NSPH
							
	 41
	  	01-661-A	  	Non-alloying core shell nanoparticles	  	12/28/2001	  	7,238,472	  	7/3/2007	  	Northwestern
University
							
	 42
	  	01-661-C	  	Non-alloying core shell nanoparticles	  	5/22/2002	  	7,147,687	  	12/12/2006	  	Northwestern
University
							
	 43
	  	01-661-E	  	Non-alloying core shell nanoparticles	  	3/26/2003	  	7,135,055	  	11/14/2006	  	Northwestern
University
							
	 44
	  	01-801-A	  	Nanoparticle imaging system and method	  	8/2/2002	  	7,110,585	  	9/19/2006	  	NSPH
							
	 45
	  	01-801-A1	  	Nanoparticle imaging system and method	  	9/8/2006	  	7,773,790	  	8/10/2010	  	NSPH
							
	 46
	  	01-897-B	  	Method for immobilizing molecules onto surfaces	  	7/12/2002	  	7,687,437	  	3/30/2010	  	NSPH

  

					
	 Page 3/13
	  	 	May 13, 2015	  

													
	 	  	 	  	 TITLE
	  	FILING
DATE	  	PATENT
NO.	  	ISSUE
DATE	  	OWNERSHIP
RIGHTS
							
	 47
	  	01-1565-A	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/8/2002	  	7,169,556	  	1/30/2007	  	Northwestern
University
							
	 48
	  	01-1633-A	  	Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes	  	7/2/2003	  	7,253,277	  	8/7/2007	  	NSPH
							
	 49
	  	01-1705-A	  	Bio-barcodes based on oligonucleotide-modified nanoparticles	  	3/27/2002	  	6,974,669	  	12/13/2005	  	Northwestern
University
							
	 50
	  	01-1705-F	  	Bio-barcodes based on oligonucleotide-modified particles	  	8/31/2005	  	7,323,309	  	1/29/2008	  	Northwestern
University
							
	 51
	  	02-035-C	  	DNA hybridization device and method	  	1/27/2003	  	7,163,823	  	1/16/2007	  	NSPH
							
	 52
	  	02-334-A	  	Method for attachment of silylated molecules to glass surfaces	  	5/28/2003	  	7,297,553	  	11/20/2007	  	NSPH
							
	 53
	  	02-334-J	  	Method for attachment of silylated molecules to glass surfaces	  	1/19/2007	  	7,476,550	  	1/13/2009	  	NSPH
							
	 54
	  	02-334-K	  	Method for attachment of silylated molecules to glass surfaces	  	1/19/2007	  	7,485,469	  	2/3/2009	  	NSPH
							
	 55
	  	02-334-L	  	Method for attachment of silylated molecules to glass surfaces	  	1/19/2007	  	7,485,470	  	2/3/2009	  	NSPH
							
	 56
	  	02-334-M	  	Method for attachment of silylated molecules to glass surfaces	  	1/19/2007	  	7,482,173	  	1/27/2009	  	NSPH
							
	 57
	  	02-338-C	  	Nanoparticle probes with Raman Spectroscopic fingerprints for analyte detection	  	5/7/2003	  	7,985,539	  	7/26/2011	  	NSPH
							
	 58
	  	08-0371-US1	  	Combined Tray and Shipping Container	  	1/17/2008	  	D587,110	  	2/24/2009	  	NSPH
							
	 59
	  	WK-90483	  	Method Of Preparing Nucleic Acids For Detection	  	11/7/2003	  	7,396,677	  	7/8/2008	  	NSPH
							
	 60
	  	92557-US	  	Disposable sample processing module for detecting nucleic acids	  	11/5/2004	  	7,695,952	  	4/13/2010	  	NSPH
							
	 61
	  	96474-US	  	Method of Denaturing and Fragmenting DNA or RNA Using Ultrasound	  	7/24/2006	  	7,625,746	  	12/1/2009	  	NSPH
							
	 62
	  	96777-US	  	System Using Disposable Self-Contained Processing Module for Detecting Nucleic Acids	  	7/24/2006	  	7,888,107	  	1/13/2011	  	NSPH

  

					
	 Page 4/13
	  	 	May 13, 2015	  

													
	 	  	 	  	 TITLE
	  	FILING
DATE	  	PATENT
NO.	  	ISSUE
DATE	  	OWNERSHIP
RIGHTS
							
	 63
	  	NU26183	  	Screening Sequence Selectivity Of Oligonucleotide-Binding Molecules Using Nanoparticle Based Colorimetric Assay	  	June 4,
2008	  	7,807,372	  	11/5/2010	  	Northwestern
University
							
	 64
	  	EPP-US1	  	Method for the identification and/or the quantification of a target compound	  	5/19/2000	  	7,321,829	  	1/22/2008	  	NSPH
							
	 65
	  	NU25066	  	Composite Particles	  	10/8/2007	  	8,512,946	  	8/20/2013	  	Northwestern
University
						
		  	AUSTRALIAN PATENTS	  		  		  		  	
							
	 66
	  	00-713-D1	  	Nanoparticles having oligonucleotides attached thereto and uses thereof	  	1-Nov-01	  	770201	  	6/3/2004	  	NSPH
							
	 67
	  	00-713-D2	  	Nanoparticles having oligonucleotides attached thereto and uses thereof	  	19-Aug-04	  	2004205147	  	4/28/2004	  	NSPH
							
	 68
	  	00-1086-C	  	Method of detection by enhancement of silver staining	  	11-Jul-01	  	2001276870	  	11/2/2006	  	Northwestern
University
							
	 69
	  	EPP-AU	  	Method for the identification and/or the quantification of a target compound	  	16-May-00	  	779752	  	6/9/2005	  	NSPH
						
		  	CANADIAN PATENTS	  		  		  		  	
							
	 70
	  	00-713-E	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	1/27/1999	  	2262018	  	10/2/2007	  	NSPH
							
	 71
	  	00-713-O	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	12/13/2001	  	2376623	  	4/19/2011	  	Joint with
Northwestern
University
							
	 72
	  	00-714-C	  	Nanoparticles with polymer shells	  	5/25/2001	  	2352362	  	2/17/2009	  	NSPH
							
	 73
	  	00-715-E	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	6/27/2002	  	2396113	  	4/7/2009	  	Joint with
Northwestern
University
							
	 74
	  	00-1086-D	  	Method of detection by enhancement of silver staining	  	1/8/2003	  	2415494	  	9/18/2007	  	Northwestern
University
							
	 75
	  	00-1085-D	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	9/10/2002	  	2402955	  	3/9/2010	  	Joint with
Northwestern
University
							
	 76
	  	01-599-D	  	Bioconjugate-nanoparticle probes	  	5/6/2004	  	CA2466656	  	7/2/2013	  	NSPH
							
	 77
	  	01-801-E	  	Nanoparticle Imaging System And Method	  	1/27/2004	  	2455118	  	1/17/2012	  	NSPH

  

					
	 Page 5/13
	  	 	May 13, 2015	  

													
	 	  	 	  	 TITLE
	  	FILING
DATE	  	PATENT
NO.	  	ISSUE
DATE	  	OWNERSHIP
RIGHTS
							
	 78
	  	01-1565-D	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	10/9/2002	  	2463323	  	12/21/2010	  	Northwestern
University
							
	 79
	  	01-1633-D	  	Nanoparticle polyanion conjugates and methods of use thereof in detecting analytes	  	12/21/2004	  	2490413	  	8/30/2011	  	NSPH
							
	 80
	  	02-338-F	  	Nanoparticle probes with raman spectroscopic fingerprints for analyte detection	  	10/27/2004	  	2483697	  	3/30/2010	  	Northwestern
University
							
	 81
	  	EPP-CA	  	Method for the identification and/or the quantification of a target compound	  	5/16/2000	  	2371658	  	1/31/2012	  	NSPH
						
		  	CHINESE PATENT	  		  		  		  	
							
	 82
	  	EPP-CN	  	Method for the identification and/or the quantification of a target compound	  	5/16/2010	  	100533146C	  	8/26/2009	  	NSPH
						
		  	JAPANESE PATENTS	  		  		  		  	
							
	 83
	  	00-713-G	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	1/29/1999	  	4245664	  	1/16/2009	  	NSPH
							
	 84
	  	00-1086-F	  	Method of detection by enhancement of silver staining	  	7/11/2001	  	3605607	  	10/8/2004	  	Northwestern
University
							
	 85
	  	01-599-F	  	Bioconjugate-nanoparticle probes	  	5/10/2004	  	4220397	  	11/21/2008	  	NSPH
							
	 86
	  	01-801-G	  	Nanoparticle imaging system and method	  	2/3/2004	  	4347053	  	7/24/2009	  	NSPH
							
	 87
	  	01-1565-F	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	4/9/2004	  	4347049	  	7/24/2009	  	Northwestern
University
							
	 88
	  	01-1705-E	  	Bio-barcodes based on oligonucleotide-modified particles	  	9/29/2003	  	4146239	  	6/27/2008	  	Northwestern
University
							
	 89
	  	02-334-G	  	Method for preparing substrates having immobilized molecules and substrates	  	11/2/2006	  	4648944	  	12/17/2010	  	NSPH
							
	 90
	  	EPP-JP	  	Method for the identification and/or the quantification of a target compound	  	5/16/2000	  	4598960	  	10/1/2010	  	NSPH
						
		  	EUROPEAN PATENTS	  		  		  		  	
							
	 91
	  	00-713-F	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	7/21/1997	  	EP 0918885	  	4/11/2007	  	NSPH
							
	 92
	  	00-713-F1	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	7/21/1997	  	EP 1818417	  	2/12/2014	  	NSPH

  

					
	 Page 6/13
	  	 	May 13, 2015	  

																			
	 	  	 	  	 TITLE
	  	FILING
DATE	 	  	PATENT
NO.	 	  	ISSUE
DATE	 	  	OWNERSHIP
RIGHTS
	 93
	  	00-713-F2	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	7/21/1997	  	  	 	GB 0918885	  	  	 	4/11/2007	  	  	NSPH
							
	 94
	  	00-713-F3	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	7/21/1997	  	  	 	CH 0918885	  	  	 	4/11/2007	  	  	NSPH
							
	 95
	  	00-713-F4	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	7/21/2007	  	  	 	DE 0918885	  	  	 	4/11/2007	  	  	NSPH
							
	 96
	  	00-713-F5	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	7/21/2007	  	  	 	ES 0918885	  	  	 	4/11/2007	  	  	NSPH
							
	 97
	  	00-713-F6	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	7/21/2007	  	  	 	FR 0918885	  	  	 	4/11/2007	  	  	NSPH
							
	 98
	  	00-713-F7	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	7/21/2007	  	  	 	IT 0918885	  	  	 	4/11/2007	  	  	NSPH
							
	 99
	  	00-713-Q-EP	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	6/26/2000	  	  	 	EP 1198591	  	  	 	3/16/2011	  	  	Joint with
Northwestern
University
							
	 100
	  	00-713-Q-DE	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	6/26/2000	  	  	 	DE 1198591	  	  	 	3/16/2011	  	  	Joint with
Northwestern
University
							
	 101
	  	00-713-Q-FR	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	6/26/2000	  	  	 	FR 1198591	  	  	 	3/16/2011	  	  	Joint with
Northwestern
University
							
	 102
	  	00-713-Q-GB	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	6/26/2000	  	  	 	GB 1198591	  	  	 	3/16/2011	  	  	Joint with
Northwestern
							
	 103
	  	00-714-E	  	Nanoparticles with polymer shells	  	 	11/30/1999	  	  	 	EP 1135682	  	  	 	7/11/2007	  	  	NSPH
							
	 104
	  	00-714-E-DE	  	Nanoparticles with polymer shells	  	 	11/30/1999	  	  	 	DE 1135682	  	  	 	7/11/2007	  	  	NSPH
							
	 105
	  	00-714-E-FR	  	Nanoparticles with polymer shells	  	 	11/30/1999	  	  	 	FR 1135682	  	  	 	7/11/2007	  	  	NSPH
							
	 106
	  	00-714-E-GB	  	Nanoparticles with polymer shells	  	 	11/30/1999	  	  	 	GB 1135682	  	  	 	7/11/2007	  	  	NSPH
							
	 107
	  	00-715-F	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	1/21/2001	  	  	 	EP 1294930	  	  	 	3/30/2011	  	  	Joint with
Northwestern
University
							
	 108
	  	00-715-F-DE	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	1/21/2001	  	  	 	DE 1294930	  	  	 	3/30/2011	  	  	Joint with
Northwestern
							
	 109
	  	00-715-F-FR	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	1/21/2001	  	  	 	FR 1294930	  	  	 	3/30/2011	  	  	Joint with
Northwestern
University

  

					
	 Page 7/13
	  	 	May 13, 2015	  

																			
	 	  	 	  	 TITLE
	  	FILING
DATE	 	  	PATENT
NO.	 	  	ISSUE
DATE	 	  	OWNERSHIP
RIGHTS
							
	 110
	  	00-715-F-GB	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	1/21/2001	  	  	 	GB 1294930	  	  	 	3/30/2011	  	  	Joint with
Northwestern
University
							
	 111
	  	00-1085-E	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	3/28/2001	  	  	 	EP 1301625	  	  	 	11/3/2010	  	  	Joint with
Northwestern
University
							
	 112
	  	00-1085-E-DE	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	3/28/2001	  	  	 	DE 1301625	  	  	 	11/3/2010	  	  	Joint with
Northwestern
University
							
	 113
	  	00-1085-E-FR	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	3/28/2001	  	  	 	FR 1301625	  	  	 	11/3/2010	  	  	Joint with
Northwestern
University
							
	 114
	  	00-1085-E-GB	  	Nanoparticles having oligonucleotides attached thereto and uses therefor	  	 	3/28/2001	  	  	 	GB 1301625	  	  	 	11/3/2010	  	  	Joint with
Northwestern
University
							
	 115
	  	00-1086-E	  	Method of detection by enhancement of silver staining	  	 	7/11/2001	  	  	 	EP 1360318	  	  	 	3/14/2007	  	  	Northwestern
University
							
	 116
	  	00-1086-E1	  	Method of detection by enhancement of silver staining	  	 	7/11/2001	  	  	 	DE 1360318	  	  	 	3/14/2007	  	  	Northwestern
University
							
	 117
	  	00-1086-E2	  	Method of detection by enhancement of silver staining	  	 	7/11/2001	  	  	 	FR 1360318	  	  	 	3/14/2007	  	  	Northwestern
University
							
	 118
	  	00-1086-E3	  	Method of detection by enhancement of silver staining	  	 	7/11/2001	  	  	 	GB 1360318	  	  	 	3/14/2007	  	  	Northwestern
University
							
	 119
	  	01-599-E	  	Bioconjugate-nanoparticle probes	  	 	11/8/2002	  	  	 	EP 1466015	  	  	 	8/6/2008	  	  	NSPH
							
	 120
	  	01-599-E-DE	  	Bioconjugate-nanoparticle probes	  	 	11/8/2002	  	  	 	DE 1466015	  	  	 	8/6/2008	  	  	NSPH
							
	 121
	  	01-599-E-FR	  	Bioconjugate-nanoparticle probes	  	 	11/8/2002	  	  	 	FR 1466015	  	  	 	8/6/2008	  	  	NSPH
							
	 122
	  	01-661-G	  	Non-alloying core shell nanoparticles	  	 	5/22/2002	  	  	 	EP 1392872	  	  	 	3/14/2007	  	  	Northwestern
University
							
	 123
	  	01-661-G1	  	Non-alloying core shell nanoparticles	  	 	5/22/2002	  	  	 	DE 1392872	  	  	 	3/14/2007	  	  	Northwestern
University
							
	 124
	  	01-661-G2	  	Non-alloying core shell nanoparticles	  	 	5/22/2002	  	  	 	FR 1392872	  	  	 	3/14/2007	  	  	Northwestern
University
							
	 125
	  	01-661-G3	  	Non-alloying core shell nanoparticles	  	 	5/22/2002	  	  	 	GB 1392872	  	  	 	3/14/2007	  	  	Northwestern
University
							
	 126
	  	01-801-F	  	Nanoparticle imaging system and method	  	 	8/2/2002	  	  	 	EP 1412536	  	  	 	2/25/2009	  	  	NSPH

  

					
	 Page 8/13
	  	 	May 13, 2015	  

																			
	 	  	 	  	 TITLE
	  	FILING
DATE	 	  	PATENT
NO.	 	  	ISSUE
DATE	 	  	OWNERSHIP
RIGHTS
							
	 127
	  	01-801-F-DE	  	Nanoparticle imaging system and method	  	 	8/2/2002	  	  	 	DE 1412536	  	  	 	2/25/2009	  	  	NSPH
							
	 128
	  	01-801-F-FR	  	Nanoparticle imaging system and method	  	 	8/2/2002	  	  	 	FR 1412536	  	  	 	2/25/2009	  	  	NSPH
							
	 129
	  	01-801-F-GB	  	Nanoparticle imaging system and method	  	 	8/2/2002	  	  	 	GB 1412536	  	  	 	2/25/2009	  	  	NSPH
							
	 130
	  	01-1633-E	  	Nanoparticle Polyanion Conjugates and Methods of Use Thereof in Detecting Analytes	  	 	7/2/2003	  	  	 	EP 1540006	  	  	 	1/7/2009	  	  	NSPH
							
	 131
	  	01-1633-E-DE	  	Nanoparticle Polyanion Conjugates and Methods of Use Thereof in Detecting Analytes	  	 	7/2/2003	  	  	 	DE 1540006	  	  	 	1/7/2009	  	  	NSPH
							
	 132
	  	01-1633-E-FR	  	Nanoparticle Polyanion Conjugates and Methods of Use Thereof in Detecting Analytes	  	 	7/2/2003	  	  	 	FR 1540006	  	  	 	1/7/2009	  	  	NSPH
							
	 133
	  	01-1633-E-GB	  	Nanoparticle Polyanion Conjugates and Methods of Use Thereof in Detecting Analytes	  	 	7/2/2003	  	  	 	GB 1540006	  	  	 	1/7/2009	  	  	NSPH
							
	 134
	  	01-1705-D	  	Bio-barcodes based on oligonucleotide-modified particles	  	 	3/27/2002	  	  	 	EP 379693	  	  	 	5/20/2009	  	  	Northwestern
University
							
	 135
	  	01-1705-D-DE	  	Bio-barcodes based on oligonucleotide-modified particles	  	 	3/27/2002	  	  	 	DE 1379693	  	  	 	5/20/2009	  	  	Northwestern
University
							
	 136
	  	01-1705-D-FR	  	Bio-barcodes based on oligonucleotide-modified particles	  	 	3/27/2002	  	  	 	FR 1379693	  	  	 	5/20/2009	  	  	Northwestern
University
							
	 137
	  	01-1705-D-GB	  	Bio-barcodes based on oligonucleotide-modified particles	  	 	3/27/2002	  	  	 	GB 1379693	  	  	 	5/20/2009	  	  	Northwestern
University
							
	 138
	  	02-035-F	  	Hybridization Device and Method	  	 	1/27/2003	  	  	 	EP1487580	  	  	 	9/14/2011	  	  	NSPH
							
	 139
	  	02-035-F-DE	  	Hybridization Device and Method	  	 	1/27/2003	  	  	 	DE1487580	  	  	 	9/14/2011	  	  	NSPH
							
	 140
	  	02-035-F-FR	  	Hybridization Device and Method	  	 	1/27/2003	  	  	 	FR1487580	  	  	 	9/14/2011	  	  	NSPH
							
	 141
	  	02-035-F-GB	  	Hybridization Device and Method	  	 	1/27/2003	  	  	 	GB1487580	  	  	 	9/14/2011	  	  	NSPH

  

					
	 Page 9/13
	  	 	May 13, 2015	  

													
	 	  	 	  	 TITLE
	  	FILING
DATE	  	PATENT
NO.	  	ISSUE
DATE	  	OWNERSHIP
RIGHTS
							
	 142
	  	02-334-F	  	Method for attachment of silylated molecules to glass surfaces	  	5/6/2005	  	EP 1759210	  	12/31/2008	  	NSPH
							
	 143
	  	02-334-F-DE	  	Method for attachment of silylated molecules to glass surfaces	  	5/6/2005	  	DE 1759210	  	12/31/2008	  	NSPH
							
	 144
	  	02-334-F-FR	  	Method for attachment of silylated molecules to glass surfaces	  	5/6/2005	  	FR 1759210	  	12/31/2008	  	NSPH
							
	 145
	  	02-334-F-GB	  	Method for attachment of silylated molecules to glass surfaces	  	5/6/2005	  	GB 1759210	  	12/31/2008	  	NSPH
							
	 146
	  	02-338-G	  	Nanoparticle probes with Raman Spectroscopic fingerprints for analyte detection	  	5/7/2003	  	EP 1499889	  	7/6/2011	  	Northwestern
University
							
	 147
	  	02-338-G-DE	  	Nanoparticle probes with Raman Spectroscopic fingerprints for analyte detection	  	5/7/2003	  	DE 1499889	  	7/6/2011	  	Northwestern
University
							
	 148
	  	02-338-G-FR	  	Nanoparticle probes with Raman Spectroscopic fingerprints for analyte detection	  	 5/7/2003
	  	FR 1499889	  	7/6/2011	  	Northwestern
University
							
	 149
	  	02-338-G-GB	  	Nanoparticle probes with Raman Spectroscopic fingerprints for analyte detection	  	5/7/2003	  	GB 1499889	  	7/6/2011	  	Northwestern
University
							
	 150
	  	02-1227-E	  	Direct SNP detection with unamplified DNA	  	12/12/2003	  	EP 1578952	  	11/23/2011	  	NSPH
							
	 151
	  	02-1227-E-DE	  	Direct SNP detection with unamplified DNA	  	12/12/2003	  	DE 1578952	  	11/23/2011	  	NSPH
							
	 152
	  	02-1227-E-FR	  	Direct SNP detection with unamplified DNA	  	12/12/2003	  	FR 1578952	  	11/23/2011	  	NSPH
							
	 153
	  	02-1227-E-GB	  	Direct SNP detection with unamplified DNA	  	12/12/2003	  	GB 1578952	  	11/23/2011	  	NSPH
							
	 154
	  	03-466-H	  	Method for detecting analytes based on evanescent illumination and scatter-based detection of nanoparticle probe complexes	  	5/27/2004	  	EP 1639370	  	9/2/2009	  	NSPH
							
	 155
	  	03-466-H-DE	  	Method for detecting analytes based on evanescent illumination and scatter-based detection of nanoparticle probe complexes	  	5/27/2004	  	DE 1639370	  	9/2/2009	  	NSPH
							
	 156
	  	03-466-H-FR	  	Method for detecting analytes based on evanescent illumination and scatter-based detection of nanoparticle probe complexes	  	5/27/2004	  	FR 1639370	  	9/2/2009	  	NSPH

  

					
	 Page 10/13
	  	 	May 13, 2015	  

													
	 	  	 	  	 TITLE
	  	FILING
DATE	  	PATENT
NO.	  	ISSUE
DATE	  	OWNERSHIP
RIGHTS
							
	 157
	  	03-466-H-GB	  	Method for detecting analytes based on evanescent illumination and scatter-based detection of nanoparticle probe complexes	  	5/27/2004	  	GB 1639370	  	9/2/2009	  	NSPH
							
	 158
	  	03-666-L	  	Bio-Barcode Based Detection Of Target Analytes	  	6/25/2004	  	EP 1649055	  	5/20/2009	  	Northwestern
University
							
	 159
	  	03-666-L-DE	  	Bio-Barcode Based Detection Of Target Analytes	  	6/25/2004	  	DE 1649055	  	5/20/2009	  	Northwestern
University
							
	 160
	  	03-666-L-FR	  	Bio-Barcode Based Detection Of Target Analytes	  	6/25/2004	  	FR 1649055	  	5/20/2009	  	Northwestern
University
							
	 161
	  	03-666-L-GB	  	Bio-Barcode Based Detection Of Target Analytes	  	6/25/2004	  	GB 1649055	  	5/20/2009	  	Northwestern
University
							
	 162
	  	03-666-R	  	Bio-Barcode Based Detection Of Target Analytes	  	5/12/2005	  	EP1747295	  	1/11/2012	  	Northwestern
University
							
	 163
	  	03-666-R-DE	  	Bio-Barcode Based Detection Of Target Analytes	  	5/12/2005	  	DE1747295	  	1/11/2012	  	Northwestern
University
							
	 164
	  	03-666-R-FR	  	Bio-Barcode Based Detection Of Target Analytes	  	5/12/2005	  	FR1747295	  	1/11/2012	  	Northwestern
University
							
	 165
	  	03-666-R-GB	  	Bio-Barcode Based Detection Of Target Analytes	  	5/12/2005	  	GB1747295	  	1/11/2012	  	Northwestern
University
							
	 166
	  	04-060-E	  	Aptamer-nanoparticle conjugates and method of use for target analyte detection	  	5/3/2005	  	EP 1766085	  	3/11/2009	  	NSPH
							
	 167
	  	04-060-E-DE	  	Aptamer-nanoparticle conjugates and method of use for target analyte detection	  	5/3/2005	  	DE 1766085	  	3/11/2009	  	NSPH
							
	 168
	  	04-060-E-FR	  	Aptamer-nanoparticle conjugates and method of use for target analyte detection	  	5/3/2005	  	FR 1766085	  	3/11/2009	  	NSPH
							
	 169
	  	04-060-E-GB	  	Aptamer-nanoparticle conjugates and method of use for target analyte detection	  	5/3/2005	  	GB 1766085	  	3/11/2009	  	NSPH

	 Page 11/13 
	 May 13, 2015 

													
	 	  	 	  	 TITLE
	  	FILING
DATE	  	PATENT
NO.	  	ISSUE
DATE	  	OWNERSHIP
RIGHTS
							
	170	  	05-539-C	  	Methods For Preparing Hybrid Substrates Comprising Dna And Antibodies And Uses Thereof	  	8/18/2006	  	EP 1915466	  	11/24/2010	  	NSPH
							
	171	  	06-373-D	  	Ultra-Sensitive Detection of Analytes	  	7/10/2007	  	EP2038656	  	5/2/2012	  	NSPH
							
	172	  	06-373-D-DE	  	Ultra-Sensitive Detection of Analytes	  	7/10/2007	  	DE2038656	  	5/2/2012	  	NSPH
							
	173	  	06-373-D-FR	  	Ultra-Sensitive Detection of Analytes	  	7/10/2007	  	FR2038656	  	5/2/2012	  	NSPH
							
	174	  	06-373-D-GB	  	Ultra-Sensitive Detection of Analytes	  	7/10/2007	  	GB2038656	  	5/2/2012	  	NSPH
							
	175	  	90483-EP	  	Method Of Preparing Nucleic Acids For Detection	  	11/4/2004	  	EP 1682681	  	8/31/2011	  	NSPH
							
	176	  	90483-DE	  	Method Of Preparing Nucleic Acids For Detection	  	11/4/2004	  	DE 1682681	  	8/31/2011	  	NSPH
							
	177	  	90483-FR	  	Method Of Preparing Nucleic Acids For Detection	  	11/4/2004	  	FR 1682681	  	8/31/2011	  	NSPH
							
	178	  	90483-GB	  	Method Of Preparing Nucleic Acids For Detection	  	11/4/2004	  	GB 1682681	  	8/31/2011	  	NSPH
							
	179	  	96474-EP	  	Method of Denaturing and Fragmenting DNA or RNA Using Ultrasound	  	7/24/2007	  	EP 2046990	  	5/7/2014	  	NSPH
							
	180	  	96777-EP	  	System Using Disposable Self-Contained Processing Module for Detecting Nucleic Acids	  	7/24/2007	  	EP 2046942	  	1/30/2015	  	NSPH

	 Page 12/13 
	 May 13, 2015 

													
	 	  	 	  	 TITLE
	  	FILING
DATE	  	PATENT
NO.	  	ISSUE
DATE	  	OWNERSHIP
RIGHTS
	181	  	96777-DE	  	System Using Disposable Self-Contained Processing Module for Detecting Nucleic Acids	  	7/24/2007	  	DE 2046942	  	1/30/2015	  	NSPH
							
	182	  	96777-FR	  	System Using Disposable Self-Contained Processing Module for Detecting Nucleic Acids	  	7/24/2007	  	FR 2046942	  	1/30/2015	  	NSPH
							
	183	  	96777-GB	  	System Using Disposable Self-Contained Processing Module for Detecting Nucleic Acids	  	7/24/2007	  	GB 2046942	  	1/30/2015	  	NSPH
							
	184	  	EPP-EP	  	Method for the identification and/or the quantification of a target compound	  	5/16/2000	  	EP 1179180	  	10/9/2002	  	NSPH
							
	185	  	EPP-EP-BE	  	Method for the identification and/or the quantification of a target compound	  	5/16/2000	  	BE 1179180	  	10/9/2002	  	NSPH
							
	186	  	EPP-EP-DE	  	Method for the identification and/or the quantification of a target compound	  	5/16/2000	  	DE 1179180	  	10/9/2002	  	NSPH
							
	187	  	EPP-EP-ES	  	Method for the identification and/or the quantification of a target compound	  	5/16/2000	  	ES 1179180	  	10/9/2002	  	NSPH
							
	188	  	EPP-EP-FR	  	Method for the identification and/or the quantification of a target compound	  	5/16/2000	  	FR 1179180	  	10/9/2002	  	NSPH
							
	189	  	EPP-EP-GB	  	Method for the identification and/or the quantification of a target compound	  	5/16/2000	  	GB 1179180	  	10/9/2002	  	NSPH
							
	190	  	EPP-EP-IT	  	Method for the identification and/or the quantification of a target compound	  	5/16/2000	  	IT 1179180	  	10/9/2002	  	NSPH
						
		  	INDIA PATENTS	  		  		  		  	
							
	191	  	EPP-IN1	  	Method for the identification and/or the quantification of a target compound	  	5/16/2000	  	206029	  	4/13/2007	  	NSPH
						
		  	MEXICAN PATENTS	  		  		  		  	
							
	192	  	EPP-MX	  	Method for the identification and/or the quantification of a target compound	  	5/16/2000	  	263062	  	12/11/2008	  	NSPH

	 Page 13/13 
	 May 13, 2015 

 
NANOSPHERE COLLATERAL — PATENT APPLICATION SCHEDULE 
  

											
	 	 	 	  	 TITLE
	  	FILING DATE	  	APPLICATION NO.	  	OWNERSHIP
		 		  	US APPLICATIONS	  		  		  	
						
	1	 	13-0742-US2	  	Multilinker Disulfide Probe For DNA or Protein Detection	  	3/14/2014	  	14/212,487	  	NSPH
						
	2	 	6114-00001	  	Diagnostic Cartridges Having Flexible Seals	  	4/22/2014	  	14/693,470	  	NSPH
						
		 		  	CANADIAN APPLICATIONS	  		  		  	
						
	3	 	03-666-J	  	Bio-Barcode Based Detection Of Target Analytes	  	12/19/2005	  	CA2529898	  	Northwestern
University
						
	4	 	03-666-P	  	Bio-Barcode Based Detection Of Target Analytes	  	10/31/2006	  	CA2565166	  	Northwestern
University
						
		 		  	JAPANESE APPLICATIONS	  		  		  	
						
	5	 	90483-JP	  	Nucleic Acids For Detection	  	5/8/2006	  	JP 2006-539673	  	NSPH

  

					
	 Page 1/1
	  	 	May 13, 2015	  

 EXHIBIT C 

Trademarks 

 NANOSPHERE COLLATERAL — TRADEMARK SCHEDULE 

 

											
	 Trademark
	  	 Country
	  	Appl No.	  	Reg. No.	  	 Class
	  	Status
	 Misc. DESIGN (NSPH Logo)
	  	USA	  	76/379,383	  	2825891	  	09 Int./l0 Int.	  	Registered
	 NANOSPHERE
	  	Canada	  	1195616	  		  		  	Published
	 NANOSPHERE
	  	China	  	92013169	  	3492602	  	10 Int.	  	Registered
	 NANOSPHERE
	  	China	  	92013170	  	3492603	  	42 Int.	  	Registered
	 NANOSPHERE
	  	Japan	  	2003-018473	  	4780186	  	10 Int., 42 Int.	  	Registered
	 NANOSPHERE
	  	Korea	  	2003-0000977	  	10998	  	10 Int., 42 Int.	  	Registered
	 NANOSPHERE
	  	Taiwan	  	92013169	  	1104151	  	10 Int.	  	Registered
	 NANOSPHERE
	  	Taiwan	  	92013170	  	193503	  	42 Int.	  	Registered
	 VERIGENE
	  	Canada	  	1176895	  		  	09 Int./10 Int.	  	Published
	 VERIGENE
	  	China	  	3784185	  	3784185	  	09 Int.	  	Registered
	 VERIGENE
	  	China	  	3784186	  	3784186	  	10 Int.	  	Registered
	 VERIGENE
	  	European Community	  	3.449.931	  	3.449.931	  	09 Int./l0 Int.	  	Registered
	 VERIGENE
	  	Hong Kong	  	300104949	  	300104949	  	09 Int./10 Int.	  	Registered
	 VERIGENE
	  	Japan	  	2003-097175	  	4770337	  	09 Int./10 Int.	  	Registered
	 VERIGENE
	  	Korea	  	2003-0048480	  	612461	  	09 Int./10 Int.	  	Registered
	 VERIGENE
	  	Taiwan	  	92064373	  	1106242	  	09 Int.	  	Registered
	 VERIGENE
	  	Taiwan	  	92064383	  	1106274	  	09 Int.	  	Registered
	 VERIGENE
	  	USA	  	78/245,832	  	2924979	  	09 Int./10 Int.	  	Registered

  
 1 

 EXHIBIT D 

Mask Works 
 None.EX-10.3

 Exhibit 10.3 

REGISTRATION RIGHTS AGREEMENT 

This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 14, 2015, by and among
Nanosphere, Inc., a Delaware corporation (the “Company”), and the holders signatory hereto (each a “Lender” and collectively, the “Lenders”). 

This Agreement is made in connection with that certain Loan and Security Agreement, dated as of May 14, 2015, among the Company and the
Lenders (the “Loan Agreement”) and the warrants issued by the Company to the Lenders in connection therewith (the “Warrants”). 

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the
receipt and adequacy of which are hereby acknowledged, the Company and the Lenders agree as follows: 
 1. Definitions. Capitalized
terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Loan Agreement. As used in this Agreement, the following terms shall have the respective meanings set forth in
this Section 1: 
 “Commission” means the United States Securities and Exchange Commission, or any successor entity or
entities, including, if applicable, the staff of the Commission. 
 “Common Stock” means the common stock, par value $0.01
per share, of the Company. 
 “Effectiveness Date” means: (a) with respect to the Initial Registration, the 120th day following the Filing Date (or the 150th day following the Filing Date in the event the Initial Registration Statement is reviewed by the
Commission), and (b) with respect to any additional Registration Statements that may be required pursuant to Section 2 hereof, the 60th day following the date on which the Company first
knows, or reasonably should have known, that such additional Registration Statement is required under such Section (or the 90th day following such date in the event such additional Registration
Statement is reviewed by the Commission). If the Effectiveness Date falls on a Saturday, Sunday or other date that the Commission is closed for business, the Effectiveness Date shall be extended to the next day on which the Commission is open for
business. 
 “Effectiveness Period” shall have the meaning set forth in Section 2(a). 

“Event” shall have the meaning set forth in Section 2(c). 

“Event Date” shall have the meaning set forth in Section 2(c). 

“Exchange Act” means the Securities Exchange Act of 1934, as amended. 

 “Filing Date” means: (a) with respect to the Initial Registration Statement
required to be filed to cover the resale by the Holders of the Registrable Securities, the 60th calendar day following the date hereof, and (b) with respect to any additional Registration Statements that may be required pursuant to
Section 2 hereof, the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities. 

“Holder” or “Holders” means the holder or holders, as the case may be, from time to time of Registrable
Securities. 
 “Indemnified Party” shall have the meaning set forth in Section 5(c). 

“Indemnifying Party” shall have the meaning set forth in Section 5(c). 

“Initial Registration Statement” shall mean the initial Registration Statement required to be filed to cover the resale by
the Holders of the Registrable Securities pursuant to Section 2(a). 
 “Issuer Filing” shall have the meaning set
forth in Section 3(j). 
 “Losses” shall have the meaning set forth in Section 5(a). 

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture,
limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 

“Proceeding” means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or
partial proceeding, such as a deposition), whether commenced or threatened. 
 “Prospectus” means the prospectus included
in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A or Rule 430B promulgated
under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements
to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 

“Reduction Securities” shall have the meaning set forth in Section 2(b). 

“Registrable Securities” means (a) the Shares issuable upon exercise of the Warrants issued in connection with the Loan
Agreement and (b) any other shares of Common Stock issued as (or issuable upon conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to, in exchange for or in

  
 2 

 
replacement of the Shares; provided, that the securities referred to in (a)-(b) above shall cease to be Registrable Securities (x) upon the sale of such securities pursuant to a
Registration Statement or (y) upon the sale of such securities pursuant to Rule 144 under the Securities Act. 
 “Registration
Statement” means each of the following: (a) an initial registration statement which is required to register the resale of the Registrable Securities, and (b) each additional registration statement, if any, contemplated by
Section 2, and including, in each case, the Prospectus, amendments and supplements to each such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference
or deemed to be incorporated by reference in such registration statement. 
 “Rule 144” means Rule 144 promulgated by the
Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“Rule 415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule. 

“SEC Guidance” means (i) any publicly-available written or oral guidance of the Commission staff, or any comments,
requirements or requests of the Commission staff and (ii) the Securities Act. 
 “Securities Act” means the Securities
Act of 1933, as amended. 
 “Shares” shall have the meaning set forth in the Warrants. 

“Trading Day” means any day on which the Common Stock is traded on the Trading Market (as defined in the Warrants). 

2. Registration. 
 (a) On
or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of all Registrable Securities not already covered by an existing and effective Registration Statement to be made on a
continuous basis pursuant to Rule 415. The Registration Statement shall be on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on
another appropriate form for such purpose) and shall contain (except if otherwise required pursuant to written comments received from the Commission upon a review of such Registration Statement) the “Plan of Distribution” in substantially
the form attached hereto as Annex A. The Company shall use its reasonable best efforts to cause each Registration Statement to be declared effective under the Securities Act as 

  
 3 

 
soon as possible but, in any event, no later than the Effectiveness Date for such Registration Statement, and shall use its reasonable best efforts to keep the Registration Statement continuously
effective under the Securities Act until the date on which all securities under such Registration Statement have ceased to be Registrable Securities (the “Effectiveness Period”). It is agreed and understood that the Company shall,
from time to time, be obligated to file one or more additional Registration Statements to cover any Registrable Securities which are not registered for resale pursuant to a pre-existing Registration Statement. 

(b) Notwithstanding anything contained herein to the contrary, in the event that the Commission limits the amount of Registrable Securities
that may be included and sold by Holders in any Registration Statement, including the Initial Registration Statement, the Company may reduce the number of Registrable Securities included in such Registration Statement on behalf of the Holders in
whole or in part (in case of an exclusion as to a portion of such Registrable Securities, such portion shall be allocated pro rata among all holders of securities covered by such Registration Statement, which may include Persons who are not Holders
party to this Agreement or the Loan Agreement, in proportion to the respective numbers of securities to be registered by each such Person over the total amount of securities to be registered on such Registration Statement) (the amount of such
excluded Registrable Securities, the “Reduction Securities”). In such event the Company shall give the Holders prompt written notice of the number of such Reduction Securities excluded. The Company shall use its reasonable best
efforts at the first opportunity that is permitted by the Commission to register for resale the Reduction Securities. Such new Registration Statement shall be on Form S-3 (except if the Company is not then eligible to register for resale the
Reduction Securities on Form S-3, in which case such registration shall be on another appropriate form for such purpose) and shall contain (except if otherwise required pursuant to written comments received from the Commission upon a review of
such Registration Statement) the “Plan of Distribution” in substantially the form attached hereto as Annex A. The Company shall use its reasonable best efforts to cause each such Registration Statement to be declared effective under
the Securities Act as soon as possible but, in any event, no later than the Effectiveness Date, and shall use its reasonable best efforts to keep such Registration Statement continuously effective under the Securities Act during the entire
Effectiveness Period. 
 3. Registration Procedures 

In connection with the Company’s registration obligations hereunder, the Company shall: 

(a) Not less than three Trading Days prior to the filing of a Registration Statement or any related Prospectus or any amendment or supplement
thereto, the Company shall furnish to the Holders copies of all such documents proposed to be filed (other than those incorporated by reference). Notwithstanding the foregoing, the Company shall not be required to furnish to the Holders any
prospectus supplement being prepared and filed solely to name new or additional selling securityholders unless such Holders are named in such prospectus supplement. In addition, in the event that any Registration Statement is on Form S-1 (or other
form which does not permit incorporation by reference), the Company shall not be required to furnish to the Holders any prospectus supplement containing information included in a report or proxy 

  
 4 

 
statement filed under the Exchange Act that would be incorporated by reference in such Registration Statement if such Registration Statement were on Form S-3 (or other form which permits
incorporation by reference). The Company shall duly consider any comments made by Holders but shall not be required to accept any such comments to which it reasonably objects. 

(b) (i) Prepare and file with the Commission such amendments, including post-effective amendments, to each Registration Statement and the
Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective as to the applicable Registrable Securities for its Effectiveness Period and prepare and file with the Commission such additional
Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement, and as so supplemented or
amended to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to each Registration Statement or any amendment thereto and, as promptly as reasonably possible
provide the Holders true and complete copies of all correspondence from and to the Commission relating to such Registration Statement that pertains to the Holders as Selling Stockholders but not any comments that would result in the disclosure to
the Holders of material and non-public information concerning the Company; and (iv) comply in all material respects with the provisions of the Securities Act and the Exchange Act with respect to the Registration Statements and the disposition
of all Registrable Securities covered by each Registration Statement. 
 (c) Notify the Holders as promptly as reasonably possible (and, in
the case of (i)(A) below, not less than three Trading Days prior to such filing) and (if requested by any such Person) confirm such notice in writing no later than one Trading Day following the day: (i)(A) when a Prospectus or any prospectus
supplement (but only to the extent notice is required under Section 3(a) above) or post-effective amendment to a Registration Statement is proposed to be filed; (B) when the Commission notifies the Company whether there will be a
“review” of such Registration Statement and whenever the Commission comments in writing on such Registration Statement (in which case the Company shall provide true and complete copies thereof and all written responses thereto to each of
the Holders that pertain to the Holders as a Selling Stockholder or to the Plan of Distribution, but not information which the Company reasonably believes would constitute material and non-public information); and (C) with respect to each
Registration Statement or any post-effective amendment, when the same has been declared effective; (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration
Statement or Prospectus or for additional information that pertains to the Holders as Selling Stockholders or the Plan of Distribution; (iii) of the issuance by the Commission of any stop order suspending the effectiveness of a Registration
Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose; (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from
qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose; (v) of the occurrence of any event or passage of time that makes the financial statements
included or incorporated by reference in a Registration Statement ineligible for inclusion or incorporation by reference therein or any statement made in such Registration Statement or Prospectus or any document incorporated or deemed to be

  
 5 

 
incorporated therein by reference untrue in any material respect or that requires any revisions to such Registration Statement, Prospectus or other documents so that, in the case of such
Registration Statement or the Prospectus, as the case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the
circumstances under which they were made, not misleading; and (vi) of the occurrence or existence of any pending development with respect to the Company that the Company believes may be material and that, in the determination of the Company,
makes it not in the best interest of the Company to allow continued availability of a Registration Statement or Prospectus; provided, that any and all of such information shall remain confidential to each Holder until such information
otherwise becomes public, unless disclosure by a Holder is required by law; provided, further, that notwithstanding each Holder’s agreement to keep such information confidential, each such Holder makes no acknowledgement that any
such information is material, non-public information. 
 (d) Use its reasonable best efforts to avoid the issuance of, or, if issued, obtain
the withdrawal of (i) any order suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at
the earliest practicable moment. 
 (e) Furnish to each Holder, without charge, at least one conformed copy of each Registration Statement
and each amendment thereto and all exhibits to the extent reasonably requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission; provided, that
the Company shall have no obligation to provide any document pursuant to this clause that is available on the EDGAR system. 
 (f) Promptly
deliver to each Holder, without charge, as many copies of each Prospectus or Prospectuses (including each form of prospectus) and each amendment or supplement thereto as such Persons may reasonably request. The Company hereby consents to the use of
such Prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto. 

(g) Prior to any public offering of Registrable Securities, use its reasonable best efforts to register or qualify or cooperate with the
selling Holders in connection with the registration or qualification (or exemption from such registration or qualification) of such Registrable Securities for offer and sale under the securities or Blue Sky laws of those jurisdictions within the
United States as any Holder reasonably requests in writing to keep each such registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things necessary or advisable to enable
the disposition in such jurisdictions of the Registrable Securities covered by the Registration Statements; provided, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so
qualified or subject the Company to any material tax in any such jurisdiction where it is not then so subject. 

  
 6 

 (h) Cooperate with the Holders to facilitate the timely preparation and delivery of certificates
representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statements, which certificates shall be free, to the extent permitted by the Warrants, of all restrictive legends, and to enable such Registrable
Securities to be in such denominations and registered in such names as any such Holders may request. 
 (i) Upon the occurrence of any event
contemplated by Section 3(c)(v), as promptly as reasonably possible, prepare a supplement or amendment, including a post-effective amendment, to the affected Registration Statements or a supplement to the related Prospectus or any document
incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as thereafter delivered, no Registration Statement nor any Prospectus will contain an untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. 

(j) If required by the FINRA Corporate Financing Department or any similar entity, promptly effect a filing with FINRA pursuant to FINRA Rule
5110 with respect to the public offering contemplated by resales of securities under the Registration Statement (an “Issuer Filing”), and pay the filing fee required by such Issuer Filing. 

4. Registration Expenses. All fees and expenses incident to the Company’s performance of or compliance with its obligations under
this Agreement (excluding any underwriting discounts and selling commissions) shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the foregoing
sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses (A) with respect to filings required to be made with the Trading Market on which the Common Stock is then
listed for trading, and (B) in compliance with applicable state securities or Blue Sky laws), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities and of printing prospectuses
if the printing of prospectuses is reasonably requested by the holders of a majority of the Registrable Securities included in the Registration Statement), (iii) messenger, telephone and delivery expenses, (iv) reasonable fees and
disbursements of counsel for the Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) reasonable fees and expenses of all other Persons retained by the Company in connection with the
consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement
(including, without limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable
Securities on any securities exchange as required hereunder. In no event shall the Company be responsible for any broker or similar commissions of any Holder or, except to the extent provided for herein, any legal fees or other costs of the Holders.

  
 7 

 5. Indemnification. 

(a) Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless
each Holder, the officers, directors, agents, partners, members, stockholders and employees of each Holder, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act)
and the officers, directors, agents, partners, members, stockholders and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs
(including, without limitation, reasonable costs of preparation and reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred, arising out of or relating to any untrue or alleged untrue statement of a
material fact contained in any Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose), or arising out of or
relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or form of prospectus or supplement thereto, in light of the circumstances under
which they were made) not misleading or any violation or alleged violation by the Company of the Securities Act or any other similar federal or state securities law or any rule or regulation promulgated thereunder applicable to the Company relating
to any such registration, qualification or compliance, except to the extent, but only to the extent, that (i) such untrue statements, alleged untrue statements, omissions or alleged omissions are based solely upon information regarding such
Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and
expressly approved in writing by such Holder expressly for use in the Registration Statement, such Prospectus or such form of Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A
hereto for this purpose) or (ii) in the case of an occurrence of an event of the type specified in Section 3(c)(ii)(v), the use by such Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing
that the Prospectus is outdated or defective and prior to the receipt by such Holder of written notice from the Company that the use of the Prospectus may be resumed or an amended or supplemented Prospectus, but only if and to the extent that
following the receipt of such written notice or the amended or supplemented Prospectus the misstatement or omission giving rise to such Loss would have been corrected. The Company shall notify the Holders promptly of the institution, threat or
assertion of any Proceeding of which the Company is aware in connection with the transactions contemplated by this Agreement. 
 (b)
Indemnification by Holders. Each Holder shall, notwithstanding any termination of this Agreement, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the
Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents, partners, members, stockholders or employees of such controlling Persons, to the fullest extent
permitted by applicable law, from and against all Losses, as incurred, arising solely out of or based solely upon: (i) for so long as the prospectus delivery requirements of the Securities Act apply to sales by such Holder, such Holder’s
failure to comply with the prospectus delivery requirements of the Securities Act or (ii) any untrue statement of a material fact contained in any Registration Statement, any Prospectus, or any form of prospectus, or in any amendment or
supplement thereto, or arising solely out of or based solely upon any 

  
 8 

 
omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus, or any form of prospectus or supplement thereto, in light of
the circumstances under which they were made) not misleading to the extent, but only to the extent that, (A) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such
Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder
expressly for use in the Registration Statement, such Prospectus or such form of Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose) or (B) in the case of an
occurrence of an event of the type specified in Section 3(c)(ii)(v), the use by such Holder of an outdated or defective Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated or defective and prior to
the receipt by such Holder of written notice from the Company that the use of the Prospectus may be resumed or an amended or supplemented Prospectus, but only if and to the extent that following the receipt of such written notice or the amended or
supplemented Prospectus the misstatement or omission giving rise to such Loss would have been corrected. In no event shall the liability of any Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder
upon the sale of the Registrable Securities giving rise to such indemnification obligation. 
 (c) Conduct of Indemnification
Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the
“Indemnifying Party”) in writing, and the Indemnifying Party shall assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in
connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent
that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have proximately and materially adversely prejudiced the Indemnifying Party. 

An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (i) the Indemnifying Party has agreed in writing to pay such fees and expenses; (ii) the Indemnifying Party shall have failed promptly
to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (iii) the named parties to any such Proceeding (including any impleaded parties) include both such
Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in
which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and
such counsel shall be at the expense of the Indemnifying Party); provided, that the Indemnifying Party shall not be liable for the fees and expenses of more than one separate firm of attorneys at any time for

  
 9 

 
all Indemnified Parties pursuant to this Section 5(c). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which
consent shall not be unreasonably withheld. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such
settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding. 

All fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating
or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within ten (10) Trading Days of written notice thereof to the Indemnifying Party (regardless of whether
it is ultimately determined that an Indemnified Party is not entitled to indemnification hereunder; provided, that the Indemnifying Party may require such Indemnified Party to undertake to reimburse all such fees and expenses to the extent it
is finally judicially determined that such Indemnified Party is not entitled to indemnification hereunder). 
 (d) Contribution. If a
claim for indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount
paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that
resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set
forth in Section 5(c), any reasonable attorneys’ or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the
indemnification provided for in this Section was available to such party in accordance with its terms. 
 The parties hereto agree that it
would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the
immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no Holder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds actually received by such Holder
from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of any damages that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No
person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 

  
 10 

 The indemnity and contribution agreements contained in this Section 5 are in addition to any
liability that the Indemnifying Parties may have to the Indemnified Parties and are not in diminution or limitation of the indemnification provisions under the Loan Agreement. 

6. Miscellaneous. 
 (a)
Remedies. In the event of a breach by the Company or by a Holder, of any of their obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under
this Agreement, including recovery of damages, will be entitled to specific performance of its rights under this Agreement. The Company and each Holder agree that monetary damages would not provide adequate compensation for any losses incurred by
reason of a breach by it of any of the provisions of this Agreement and hereby further agree that, in the event of any action for specific performance in respect of such breach, it shall waive the defense that a remedy at law would be adequate. 

(b) Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as
applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement. 
 (c) Discontinued
Disposition. Each Holder agrees by its acquisition of such Registrable Securities that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(c), such Holder will forthwith discontinue
disposition of such Registrable Securities under the Registration Statement until such Holder’s receipt of the copies of the supplemented Prospectus and/or amended Registration Statement or until it is advised in writing by the Company that the
use of the applicable Prospectus may be resumed, and, in either case, has received copies of any additional or supplemental filings that are incorporated or deemed to be incorporated by reference in such Prospectus or Registration Statement. The
Company may provide appropriate stop orders to enforce the provisions of this paragraph. 
 (d) Furnishing of Information. Each
Holder shall furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it, as shall be reasonably requested by the Company
to effect the registration of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably request. 

(e) Piggy-Back Registrations. If at any time during the Effectiveness Period, except as contemplated by Section 2(b) hereof, there
is not an effective Registration Statement covering all of the Registrable Securities and the Company shall determine to prepare and file with the Commission a registration statement relating to an offering for its own account or the account of
others under the Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any
acquisition of any entity or business or equity securities issuable in connection with the stock option or other employee benefit plans, 

  
 11 

 
then the Company shall send to each Holder a written notice of such determination and, if within fifteen (15) days after the date of such notice, any such Holder shall so request in writing,
the Company shall include in such registration statement all or any part of such Registrable Securities such Holder requests to be registered; provided, however, that the Company shall not be required to register any Registrable
Securities pursuant to this Section 6(e) that are the subject of a then effective Registration Statement. 
 (f) Reports Under the
Exchange Act. With a view to making available to the Holder the benefits of Rule 144 and any other rule or regulation of the Commission that may at any time permit the Holder to sell securities of the Company to the public without registration,
the Company agrees, for so long as the Holder holds (i) all or any portion of the Shares issued pursuant to the Warrants, and (ii) any other shares of Common Stock issued as (or issuable upon conversion or exercise of any warrant, right or
other security which is issued as) a dividend or other distribution with respect to, in exchange for or in replacement of the Shares, to use its commercially reasonable efforts to: 

(A) make and keep public information available, as those terms are understood and defined in Rule 144, at all times on and after the date
hereof; 
 (B) file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act
and the Exchange Act (or obtain extensions in respect thereof and file within the applicable grace period); and 
 (C) furnish to the
Holder, so long as the Holder owns (1) all or any portion of the Shares issued pursuant to the Warrants, and (2) any other shares of Common Stock issued as (or issuable upon conversion or exercise of any warrant, right or other security
which is issued as) a dividend or other distribution with respect to, in exchange for or in replacement of the Shares, forthwith upon request (x) a written statement by the Company that it has complied with the reporting requirements of Rule
144, the Securities Act and the Exchange Act and (y) such other information as may be reasonably requested to avail the Holder of any rule or regulation of the Commission that permits the selling of any such securities without registration.

 (g) Amendments and Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed by the
Company and the Holder or Holders (as applicable) of no less than two-thirds of the then outstanding Registrable Securities. The Company shall provide prior notice to all Holders of any proposed waiver or amendment. No waiver of any default with
respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any
delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right. 

  
 12 

 (h) Notices. All notices, requests, consents and other communications hereunder shall be
in writing, shall be sent by confirmed facsimile or electronic mail, or mailed by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of
facsimile or electronic mail transmission, or when so received in the case of mail or courier, and addressed as follows: 
  

			
	If to the Company:		 NANOSPHERE, INC.
 4088 Commercial Avenue

Northbrook, IL 60062
 Attn: Chief Financial Officer

Fax: (847) 400-9199
 Email: awallin@nanosphere.us

		
	with a copy (which shall not constitute notice) to:		 SEYFARTH SHAW LLP
 620 Eighth Avenue

New York, NY 10018-1405
 Attn: Blake Hornick

Fax: (212) 218-5526
 Email: BHornick@seyfarth.com

		
	If to NSPH Funding LLC:		 NSPH Funding LLC
 c/o Life Sciences
Alternative Funding LLC
 50 Main Street
 Suite 1000

White Plains, NY 10606
 Attention: Stephen J. DeNelsky

Email: steve@lsafunding.com

		
	with a copy (which shall not constitute notice) to:		 LATHAM & WATKINS LLP
 505 Montgomery
Street
 Suite 2000
 San Francisco, CA 94111-6538

Attn: Haim Zaltzman
 Fax: 415.395.8095

Email: haim.zaltzman@lw.com

		
	If to SWK Funding LLC:		 SWK Funding LLC
 14755 Preston Road, Suite
105
 Dallas, Texas 75254
 Attention: Brett Pope

Fax:
 Email: notifications@swkhold.com

		
	with a copy (which shall not constitute notice) to:		 Holland & Knight LLP
 200 Crescent
Court
 Dallas, TX 75201
 Attn: Ryan Magee

Fax: (214) 964-9501
 Email:
ryan.magee@hklaw.com

  
 13 

			
	If to any other Person who is then the registered Holder:		To the address of such Holder as it appears in the stock transfer books of the Company

 or such other address as may be designated in writing hereafter, in the same manner, by such Person. 

(i) Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of
each of the parties and shall inure to the benefit of each Holder. Each Holder may assign its respective rights hereunder in the manner and to the Persons as permitted under the applicable Warrant. 

(j) Execution and Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed shall be
deemed to be an original and, all of which taken together shall constitute one and the same Agreement. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid binding obligation of the party
executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature were the original thereof. 

(k) Governing Law, Venue and Jury Trial Waiver. 

(i) Waiver of Jury Trial. EACH PARTY UNCONDITIONALLY WAIVES ANY AND ALL RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED
UPON OR ARISING OUT OF THIS AGREEMENT. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT. THIS WAIVER IS IRREVOCABLE. THIS WAIVER MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING. THE
WAIVER ALSO SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS AGREEMENT. THIS AGREEMENT MAY BE FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT. 

(i) 
 (ii) Governing Law
and Jurisdiction. THIS AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL IN ALL RESPECTS BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK (WITHOUT REGARD TO THE CONFLICT OF LAWS
PRINCIPLES THAT WOULD RESULT IN THE APPLICATION OF ANY LAWS OTHER THAN THE LAWS OF THE STATE OF NEW YORK), INCLUDING ALL MATTERS OF CONSTRUCTION, VALIDITY AND PERFORMANCE. 

(iii) Submission to Jurisdiction. Any legal action or proceeding with respect to this Agreement shall be brought exclusively in the
courts of the State of New York located in the City of New York, Borough of Manhattan, or of the United States of America for 

  
 14 

 
the Southern District of New York and, by execution and delivery of this Agreement, he Company hereby accepts, generally and unconditionally, the jurisdiction of the aforesaid courts. The parties
hereto hereby irrevocably waive any objection, including any objection to the laying of venue or based on the grounds of forum non conveniens, that any of them may now or hereafter have to the bringing of any such action or proceeding in such
jurisdictions. 
 (iv) Service of Process. The Company irrevocably waives personal service of any and all legal process, summons,
notices and other documents and other service of process of any kind and consents to such service in any suit, action or proceeding brought in the United States of America with respect to or otherwise arising out of or in connection with this
Agreement by any means permitted by applicable requirements of law, including by the mailing thereof (by registered or certified mail, postage prepaid) to the address of the Company specified herein (and shall be effective when such mailing shall be
effective, as provided therein). The Company agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. 

(v) Non-exclusive Jurisdiction. Nothing contained in this Section 6(k) shall affect the right of the Holders to serve process in
any other manner permitted by applicable requirements of law or commence legal proceedings or otherwise proceed against the Company in any other jurisdiction.

(l) Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law. 

(m) Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be
invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall
use their reasonable best efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the
intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. 

(n) Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning
hereof. 
 (o) Independent Nature of Holders’ Obligations and Rights. The obligations of each Holder hereunder is several and
not joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder hereunder. Nothing contained herein and no action taken by any Holder pursuant
hereto shall be deemed to constitute the Holder s as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holders are in any way acting in concert with respect to such obligations or the
transactions contemplated by this Agreement. Each Holder acknowledges that no other Holder has acted as agent for such Holder in connection with this Agreement and that no other Holder will be acting as agent of such

  
 15 

 
Holder in connection with monitoring its investment in the Shares or enforcing its rights under this Agreement. Each Holder shall be entitled to protect and enforce its rights, including without
limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such purpose. 

[Remainder of page intentionally left blank] 

  
 16 

 IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date
first written above. 
 COMPANY: 
 NANOSPHERE, INC. 

By /s/ Michael McGarrity 
 Name: Michael McGarrity 

Title: CEO 
 LENDERS: 

NSPH Funding LLC 
 By /s/ Stephen J. DeNelsky 

Name: Stephen J. DeNelsky 
 Title: President 

SWK FUNDING LLC 
 By /s/ Brett Pope 

Name: Brett Pope 
 Title: CEO 

[Signature Page to Registration Rights Agreement] 

 ANNEX A 

PLAN OF DISTRIBUTION 
 The
selling stockholders and any of their pledgees, donees, transferees, assignees or other successors-in-interest may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common
stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market
price, at varying prices determined at the time of sale, or at negotiated prices. The selling stockholders may use one or more of the following methods when disposing of the shares or interests therein: 

 

	 	•	 	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

  

	 	•	 	block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; 

 

	 	•	 	through brokers, dealers or underwriters that may act solely as agents; 

  

	 	•	 	purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

  

	 	•	 	an exchange distribution in accordance with the rules of the applicable exchange; 

  

	 	•	 	privately negotiated transactions; 

  

	 	•	 	short sales; 

  

	 	•	 	through the writing or settlement of options or other hedging transactions entered into after the effective date of the registration statement of which this prospectus is a part, whether through an options exchange or
otherwise; 

  

	 	•	 	broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; 

  

	 	•	 	a combination of any such methods of disposition; and 

  

	 	•	 	any other method permitted pursuant to applicable law. 

 The selling stockholders may also sell
shares under Rule 144 under the Securities Act of 1933, as amended, or Securities Act, if available, rather than under this prospectus. 

Broker-dealers engaged by the selling stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the selling 

 
stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The selling stockholders do not expect these commissions and
discounts to exceed what is customary in the types of transactions involved. 
 The selling stockholders may from time to time pledge or
grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell shares of common stock from time to time
under this prospectus, or under a supplement or amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in
interest as selling stockholders under this prospectus. 
 Upon being notified in writing by a selling stockholder that any material
arrangement has been entered into with a broker-dealer for the sale of common stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, we will file a supplement to this
prospectus, if required, pursuant to Rule 424(b) under the Securities Act, disclosing (i) the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the number of shares involved, (iii) the price at
which such shares of common stock were sold, (iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the
information set out or incorporated by reference in this prospectus, and (vi) other facts material to the transaction. In addition, upon being notified in writing by a selling stockholder that a donee or pledge intends to sell more than 500
shares of common stock, we will file a supplement to this prospectus if then required in accordance with applicable securities law. 
 The
selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. 

In connection with the sale of the shares of common stock or interests in shares of common stock, the selling stockholders may enter into
hedging transactions after the effective date of the registration statement of which this prospectus is a part with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging
the positions they assume. The selling stockholders may also sell shares of common stock short after the effective date of the registration statement of which this prospectus is a part and deliver these securities to close out their short positions,
or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions after the effective date of the registration statement of which this prospectus is
a part with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such
broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). 

  
 A-2 

 The selling stockholders and any broker-dealers or agents that are involved in selling the shares
may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by
them may be deemed to be underwriting commissions or discounts under the Securities Act. The maximum commission or discount to be received by any member of the Financial Industry Regulatory Authority (FINRA) or independent broker-dealer will not be
greater than 8% of the initial gross proceeds from the sale of any security being sold. 
 We have advised the selling stockholders that
they are required to comply with Regulation M promulgated under the Securities and Exchange Act during such time as they may be engaged in a distribution of the shares. The foregoing may affect the marketability of the common stock. 

The aggregate proceeds to the selling securityholders from the sale of the common stock offered by them will be the purchase price of the
common stock less discounts or commissions, if any. Each of the selling securityholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made
directly or through agents. We will not receive any of the proceeds from this offering. 
 We are required to pay all fees and expenses
incident to the registration of the shares. We have agreed to indemnify the selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act or otherwise. 

We have agreed with the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until
such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement of which this prospectus forms a part or pursuant to Rule 144 of the Securities Act. 

  
 A-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]